Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HPV test brings Digene to profit:

This article was originally published in Clinica

Executive Summary

Digene (Gaithersburg, Maryland) has reported its first profitable quarter as it saw strong growth in sales of its human papillomavirus (HPV) test. The test gained approval in the US as a primary screening tool for cervical cancer five months ago. The company reported net income of $0.3m in the fourth quarter ended June 30, on sales up by 50% to $19.1m. HPV test sales rose by 68% to $16m. The company is building up its sales presence in Europe and elsewhere and expects 2004 full-year sales to reach $90-95m. 2003 sales were $63m (+29%), with a net loss of $4.3m.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel